NCT01649466View on ClinicalTrials.gov

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

LAF237

Vildagliptin will be used as commercially available tablets of 50mg.

DRUG

Protaphane

Protaphane will be used as commercially available injection pens

Trial Locations (53)

10115

Novartis Investigative Site, Berlin

10117

Novartis Investigative Site, Berlin

10627

Novartis Investigative Site, Berlin

12347

Novartis Investigative Site, Berlin

13189

Novartis Investigative Site, Berlin

13597

Novartis Investigative Site, Berlin

14469

Novartis Investigative Site, Potsdam

18233

Novartis Investigative Site, Schliemannstadt Neubukow

23858

Novartis Investigative Site, Reinfeld

30900

Novartis Investigative Site, Wedemark

31139

Novartis Investigative Site, Hildesheim

32549

Novartis Investigative Site, Bad Oeynhausen

32584

Novartis Investigative Site, Löhne

34125

Novartis Investigative Site, Kassel

34127

Novartis Investigative Site, Kassel

35584

Novartis Investigative Site, Wetzlar-Naunheim

36037

Novartis Investigative Site, Fulda

37574

Novartis Investigative Site, Einbeck

38836

Novartis Investigative Site, Anderbeck

39120

Novartis Investigative Site, Magdeburg

44137

Novartis Investigative Site, Dortmund

44653

Novartis Investigative Site, Herne

45219

Novartis Investigative Site, Essen

45276

Novartis Investigative Site, Essen

45468

Novartis Investigative Site, Mülheim

47533

Novartis Investigative Site, Kleve

49536

Novartis Investigative Site, Lienen

51069

Novartis Investigative Site, Cologne

55116

Novartis Investigative Site, Mainz

55545

Novartis Investigative Site, Bad Kreuznach

56727

Novartis Investigative Site, Mayen

63571

Novartis Investigative Site, Gelnhausen

66386

Novartis Investigative Site, Saint Ingbert - Oberwuerzbach

66709

Novartis Investigative Site, Weiskirchen

66740

Novartis Investigative Site, Saarlouis

70191

Novartis Investigative Site, Stuttgart

72336

Novartis Investigative Site, Balingen

76676

Novartis Investigative Site, Graben-Neudorf

78054

Novartis Investigative Site, Villingen-Schwenningen

80339

Novartis Investigative Site, München

81373

Novartis Investigative Site, München

86150

Novartis Investigative Site, Augsburg

88239

Novartis Investigative Site, Wangen

94315

Novartis Investigative Site, Straubing

94574

Novartis Investigative Site, Wallerfing

96269

Novartis Investigative Site, Grossheirath-Rossach

97072

Novartis Investigative Site, Würzburg

01099

Novartis Investigative Site, Dresden

01309

Novartis Investigative Site, Dresden

06295

Novartis Investigative Site, Eisleben Lutherstadt

04910

Novartis Investigative Site, Elsterwerda

04758

Novartis Investigative Site, Oschatz

04808

Novartis Investigative Site, Wurzen

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY